Pfizer challenges Roche blockbusters with 3 biosim launches at discounts from 22% to 24%

24th January 2020 Uncategorised 0

Pfizer isn’t giving up in biosims despite early challenges. This week, it unveiled launches to three Roche blockbusters, with two already on the market. The biosims target Roche’s Avastin, Herceptin and Rituxan with discounts ranging from 22% to 24%. Together, the Roche meds pulled in more than $10 billion at peak.

More: Pfizer challenges Roche blockbusters with 3 biosim launches at discounts from 22% to 24%
Source: fierce